Related posts
Top Covid-19 Vaccine Stocks to Bet on the Immunization Race (Updated)COVID-19 Stocks to Save Your RRSP + Forecasts and Facts (Updated)Battle of the Top Dividend ETFs : CanadaThis summary was created by AI, based on 3 opinions in the last 12 months.
Sanofi-Aventis (SNY) has garnered positive attention from various experts, indicating a promising outlook. The recent earnings report revealed consistent sales growth exceeding 10% for the third consecutive quarter, with prudent financial management evident in their strategy to draw down cash reserves for debt retirement and share buybacks. Analysts have highlighted SNY's attractive valuation metrics, trading at 13x to 25x earnings, with a return on equity (ROE) ranging from 25% to 27%. Recommendations include trailing stop-loss adjustments and target price predictions between $58 and $64, suggesting substantial upside potential. Despite recent challenges including the spin-off of consumer healthcare operations, the stock appears to be stabilizing and is poised for potential gains, making it a favored choice among analysts.
SNY touched the bottom of its range in October 2023 on weak earnings and news that it would spin-off its consumer healthcare operations. The stock looks to be breaking out and while very hard to predict we think it is possible it trades in a higher new range. The drop last year was likely a one-off driven by the spin-off news, and barring a significant news item as such or consistently weak earnings, we would be surprised if it got back to the low-end of its range.
Unlock Premium - Try 5i Free
Sanofi-Aventis is a American stock, trading under the symbol SNY-N on the New York Stock Exchange (SNY). It is usually referred to as NYSE:SNY or SNY-N
In the last year, 1 stock analyst published opinions about SNY-N. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Sanofi-Aventis.
Sanofi-Aventis was recommended as a Top Pick by on . Read the latest stock experts ratings for Sanofi-Aventis.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
1 stock analyst on Stockchase covered Sanofi-Aventis In the last year. It is a trending stock that is worth watching.
On 2025-03-13, Sanofi-Aventis (SNY-N) stock closed at a price of $57.61.
We reiterate SNY as a TOP PICK. Recently reported earnings showed sales growth for the third consecutive quarter that exceeded 10%. Cash reserves are prudently being drawn down to retire debt and buy back shares. It trades at 13x earnings, 1.6x book and supports a 25% ROE. We recommend trailing up the stop (from $42) to $47, looking to achieve $64 -- upside potential of 20%. Yield 2.7%
(Analysts’ price target is $64.00)